vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Rapid7, Inc. (RPD). Click either name above to swap in a different company.

Rapid7, Inc. is the larger business by last-quarter revenue ($217.4M vs $168.4M, roughly 1.3× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 0.5%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 3.0%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

Rapid7, Inc. is a leading global cybersecurity company that offers a full portfolio of solutions including vulnerability management, threat detection and response, cloud security, and security analytics. It serves enterprises, SMBs, and public sector entities across industries like tech, healthcare, finance, and manufacturing worldwide, helping clients address and mitigate cyber risks efficiently.

ESPR vs RPD — Head-to-Head

Bigger by revenue
RPD
RPD
1.3× larger
RPD
$217.4M
$168.4M
ESPR
Growing faster (revenue YoY)
ESPR
ESPR
+143.2% gap
ESPR
143.7%
0.5%
RPD
Faster 2-yr revenue CAGR
ESPR
ESPR
Annualised
ESPR
10.6%
3.0%
RPD

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ESPR
ESPR
RPD
RPD
Revenue
$168.4M
$217.4M
Net Profit
$3.1M
Gross Margin
68.9%
Operating Margin
50.6%
1.0%
Net Margin
1.4%
Revenue YoY
143.7%
0.5%
Net Profit YoY
44.1%
EPS (diluted)
$0.32
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
RPD
RPD
Q4 25
$168.4M
$217.4M
Q3 25
$87.3M
$218.0M
Q2 25
$82.4M
$214.2M
Q1 25
$65.0M
$210.3M
Q4 24
$69.1M
$216.3M
Q3 24
$51.6M
$214.7M
Q2 24
$73.8M
$208.0M
Q1 24
$137.7M
$205.1M
Net Profit
ESPR
ESPR
RPD
RPD
Q4 25
$3.1M
Q3 25
$-31.3M
$9.8M
Q2 25
$-12.7M
$8.3M
Q1 25
$-40.5M
$2.1M
Q4 24
$2.2M
Q3 24
$-29.5M
$15.4M
Q2 24
$-61.9M
$6.5M
Q1 24
$61.0M
$1.4M
Gross Margin
ESPR
ESPR
RPD
RPD
Q4 25
68.9%
Q3 25
70.2%
Q2 25
70.6%
Q1 25
71.7%
Q4 24
69.5%
Q3 24
70.6%
Q2 24
70.7%
Q1 24
70.3%
Operating Margin
ESPR
ESPR
RPD
RPD
Q4 25
50.6%
1.0%
Q3 25
-11.4%
2.7%
Q2 25
8.6%
1.6%
Q1 25
-34.0%
-0.0%
Q4 24
-6.4%
3.4%
Q3 24
-31.0%
6.0%
Q2 24
3.5%
2.5%
Q1 24
52.5%
4.7%
Net Margin
ESPR
ESPR
RPD
RPD
Q4 25
1.4%
Q3 25
-35.9%
4.5%
Q2 25
-15.4%
3.9%
Q1 25
-62.2%
1.0%
Q4 24
1.0%
Q3 24
-57.2%
7.2%
Q2 24
-83.9%
3.1%
Q1 24
44.3%
0.7%
EPS (diluted)
ESPR
ESPR
RPD
RPD
Q4 25
$0.32
$0.05
Q3 25
$-0.16
$0.15
Q2 25
$-0.06
$0.13
Q1 25
$-0.21
$0.03
Q4 24
$-0.14
$0.08
Q3 24
$-0.15
$0.21
Q2 24
$-0.33
$0.09
Q1 24
$0.34
$0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
RPD
RPD
Cash + ST InvestmentsLiquidity on hand
$167.9M
$474.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$-302.0M
$154.7M
Total Assets
$465.9M
$1.7B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
RPD
RPD
Q4 25
$167.9M
$474.7M
Q3 25
$92.4M
$407.1M
Q2 25
$86.1M
$511.7M
Q1 25
$114.6M
$493.5M
Q4 24
$144.8M
$521.7M
Q3 24
$144.7M
$443.7M
Q2 24
$189.3M
$442.6M
Q1 24
$226.6M
$411.7M
Stockholders' Equity
ESPR
ESPR
RPD
RPD
Q4 25
$-302.0M
$154.7M
Q3 25
$-451.4M
$127.2M
Q2 25
$-433.5M
$90.4M
Q1 25
$-426.2M
$52.7M
Q4 24
$-388.7M
$17.7M
Q3 24
$-370.2M
$-5.1M
Q2 24
$-344.2M
$-52.6M
Q1 24
$-294.3M
$-86.4M
Total Assets
ESPR
ESPR
RPD
RPD
Q4 25
$465.9M
$1.7B
Q3 25
$364.0M
$1.7B
Q2 25
$347.1M
$1.6B
Q1 25
$324.0M
$1.6B
Q4 24
$343.8M
$1.7B
Q3 24
$314.1M
$1.6B
Q2 24
$352.3M
$1.5B
Q1 24
$373.1M
$1.5B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
RPD
RPD
Operating Cash FlowLast quarter
$45.2M
$37.6M
Free Cash FlowOCF − Capex
$36.4M
FCF MarginFCF / Revenue
16.8%
Capex IntensityCapex / Revenue
0.0%
0.5%
Cash ConversionOCF / Net Profit
12.01×
TTM Free Cash FlowTrailing 4 quarters
$146.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
RPD
RPD
Q4 25
$45.2M
$37.6M
Q3 25
$-4.3M
$39.0M
Q2 25
$-31.4M
$47.5M
Q1 25
$-22.6M
$29.8M
Q4 24
$-35.0M
$63.8M
Q3 24
$-35.3M
$44.0M
Q2 24
$-7.2M
$32.9M
Q1 24
$53.8M
$31.1M
Free Cash Flow
ESPR
ESPR
RPD
RPD
Q4 25
$36.4M
Q3 25
$34.8M
Q2 25
$46.6M
Q1 25
$28.4M
Q4 24
$62.6M
Q3 24
$-35.5M
$42.6M
Q2 24
$-7.3M
$32.6M
Q1 24
$53.8M
$30.4M
FCF Margin
ESPR
ESPR
RPD
RPD
Q4 25
16.8%
Q3 25
16.0%
Q2 25
21.8%
Q1 25
13.5%
Q4 24
28.9%
Q3 24
-68.7%
19.9%
Q2 24
-9.9%
15.7%
Q1 24
39.0%
14.8%
Capex Intensity
ESPR
ESPR
RPD
RPD
Q4 25
0.0%
0.5%
Q3 25
0.0%
1.9%
Q2 25
0.0%
0.4%
Q1 25
0.0%
0.6%
Q4 24
0.0%
0.5%
Q3 24
0.3%
0.6%
Q2 24
0.1%
0.1%
Q1 24
0.1%
0.3%
Cash Conversion
ESPR
ESPR
RPD
RPD
Q4 25
12.01×
Q3 25
3.97×
Q2 25
5.70×
Q1 25
14.14×
Q4 24
29.36×
Q3 24
2.85×
Q2 24
5.03×
Q1 24
0.88×
22.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

RPD
RPD

Products$209.1M96%
Services$8.2M4%

Related Comparisons